X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 9,480,000 shares, a decrease of 14.3% from the February 13th total of 11,060,000 shares. Approximately 5.7% of the company’s stock are sold short. Based on an average daily volume of 4,100,000 shares, the short-interest ratio is currently 2.3 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a research report on Friday, February 7th.
Check Out Our Latest Analysis on X4 Pharmaceuticals
Insider Buying and Selling
Institutional Investors Weigh In On X4 Pharmaceuticals
Hedge funds have recently made changes to their positions in the company. Verition Fund Management LLC purchased a new stake in shares of X4 Pharmaceuticals in the 3rd quarter worth $30,000. Cantor Fitzgerald L. P. purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth $30,000. Atria Wealth Solutions Inc. purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth $44,000. Wells Fargo & Company MN lifted its holdings in shares of X4 Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock worth $58,000 after buying an additional 26,763 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after buying an additional 22,485 shares during the period. 72.03% of the stock is currently owned by hedge funds and other institutional investors.
X4 Pharmaceuticals Price Performance
XFOR opened at $0.29 on Wednesday. The business has a fifty day moving average of $0.48 and a 200 day moving average of $0.54. X4 Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $1.60. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The stock has a market cap of $50.24 million, a P/E ratio of -3.27 and a beta of 0.39.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.
Featured Stories
- Five stocks we like better than X4 Pharmaceuticals
- What is a Stock Market Index and How Do You Use Them?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 Must-Own Stocks to Build Wealth This Decade
- What Are Some of the Best Large-Cap Stocks to Buy?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.